scholarly journals Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression

2021 ◽  
Author(s):  
Ksenia S. Maslyonkina ◽  
Alexandra K. Konyukova ◽  
Darya Y. Alexeeva ◽  
Mikhail Y. Sinelnikov ◽  
Liudmila M. Mikhaleva
Keyword(s):  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Molecular Genetic ◽  
Neoplastic Progression

Sa1987 AMACR Immunohistochemistry for Prediction of Neoplastic Progression in Patients With Barrett's Esophagus: Results From a Large Multicentre Prospective Cohort

2013 ◽  
Vol 144 (5) ◽  
pp. S-352
Author(s):  
Florine Kastelein ◽  
Katharina Biermann ◽  
Sophie van Olphen ◽  
Ewout W. Steyerberg ◽  
Leendert Looijenga ◽  
...  
Keyword(s):  
Barrett’S Esophagus ◽  
Prospective Cohort ◽  
Barrett's Esophagus ◽  
Neoplastic Progression

Plasma and Esophageal Mucosal Levels of Vitamin C: Role in the Pathogenesis and Neoplastic Progression of Barrett's Esophagus

2004 ◽  
Vol 49 (6) ◽  
pp. 914-919 ◽  
Author(s):  
A. Fountoulakis ◽  
I. G. Martin ◽  
K. L. M. White ◽  
M. F. Dixon ◽  
J. E. Cade ◽  
...  
Keyword(s):  
Vitamin C ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Neoplastic Progression

Barrett's esophagus: Cell cycle abnormalities in advancing stages of neoplastic progression

1993 ◽  
Vol 105 (1) ◽  
pp. 119-129 ◽  
Author(s):  
Brian J. Reid ◽  
Carissa A. Sanchez ◽  
Patricia L. Blount ◽  
Douglas S. Levine
Keyword(s):  
Cell Cycle ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Neoplastic Progression

10 - Prediction in Surveillance of Barrett's Esophagus: The Effect of Multiple Meaurements of Biomarkers on the Estimated Neoplastic Progression Risk

2018 ◽  
Vol 154 (6) ◽  
pp. S-4
Author(s):  
Carlijn A. Roumans ◽  
Manon Spaander ◽  
Iris Lansdorp-Vogelaar ◽  
Katharina Biermann ◽  
Marco J. Bruno ◽  
...  
Keyword(s):  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Neoplastic Progression ◽  
Progression Risk

scholarly journals Is Malignant Potential of Barrett’s Esophagus Predictable by Endoscopy Findings?

Life ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 244
Author(s):  
Yuji Amano ◽  
Norihisa Ishimura ◽  
Shunji Ishihara
Keyword(s):  
Protein Expression ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Cellular Proliferation ◽  
Narrow Band Imaging ◽  
Malignant Potential ◽  
Cyclooxygenase 2 ◽  
Neoplastic Progression ◽  
White Light Endoscopy ◽  
Endoscopic Findings

Given that endoscopic findings can be used to predict the potential of neoplastic progression in Barrett’s esophagus (BE) cases, the detection rate of dysplastic Barrett’s lesions may become higher even in laborious endoscopic surveillance because a special attention is consequently paid. However, endoscopic findings for effective detection of the risk of neoplastic progression to esophageal adenocarcinoma (EAC) have not been confirmed, though some typical appearances are suggestive. In the present review, endoscopic findings that can be used predict malignant potential to EAC in BE cases are discussed. Conventional results obtained with white light endoscopy, such as length of BE, presence of esophagitis, ulceration, hiatal hernia, and nodularity, are used as indicators of a higher risk of neoplastic progression. However, there are controversies in some of those findings. Absence of palisade vessels may be also a new candidate predictor, as that reveals degree of intense inflammation and of cyclooxygenase-2 protein expression with accelerated cellular proliferation. Furthermore, an open type of mucosal pattern and enriched stromal blood vessels, which can be observed by image-enhanced endoscopy, including narrow band imaging, have been confirmed as factors useful for prediction of neoplastic progression of BE because they indicate more frequent cyclooxygenase-2 protein expression along with accelerated cellular proliferation. Should the malignant potential of BE be shown predictable by these endoscopic findings, that would simplify methods used for an effective surveillance, because patients requiring careful monitoring would be more easily identified. Development in the near future of a comprehensive scoring system for BE based on clinical factors, biomarkers and endoscopic predictors is required.

Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett’s esophagus: a systematic review and meta-analysis

Endoscopy ◽  
2019 ◽  
Vol 51 (07) ◽  
pp. 665-672 ◽  
Author(s):  
Viveksandeep Thoguluva Chandrasekar ◽  
Nour Hamade ◽  
Madhav Desai ◽  
Tarun Rai ◽  
Venkata Subhash Gorrepati ◽  
...  
Keyword(s):  
Systematic Review ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Meta Analysis ◽  
Significant Heterogeneity ◽  
Neoplastic Progression ◽  
Number Of Patients ◽  
The Mean ◽  
Surveillance Endoscopy

Abstract Background Although shorter lengths of Barrett’s esophagus (BE) have been associated with a lower risk of neoplastic progression, precise estimates have varied, especially for non-dysplastic BE (NDBE) only. Therefore, current US guidelines do not provide specific recommendations on surveillance intervals based on BE length. We performed a systematic review and meta-analysis of the published literature to examine neoplastic progression rates of NDBE based on BE length. Methods PubMed, Cochrane, Google Scholar, and Embase were comprehensively searched. Studies reporting progression rates in patients with NDBE and > 1 year of follow-up were included. The number of patients progressing to esophageal adenocarcinoma (EAC) and high grade dysplasia (HGD)/EAC in individual studies and the mean follow-up were recorded to derive person-years of follow-up. Pooled rates of progression to EAC and HGD/EAC based on BE length (< 3 cm vs. ≥ 3 cm) were calculated. Results Of the 486 initial studies identified, 10 met the inclusion/exclusion criteria. These included a total of 4097 NDBE patients; 1979 with short-segment BE (SSBE; 10 773 person-years of follow-up) and 2118 with long-segment BE (LSBE; 12 868 person-years). The annual rates of progression to EAC were significantly lower for SSBE compared with LSBE: 0.06 % (95 % confidence interval 0.01 % – 0.10 %) vs. 0.31 % (0.21 % – 0.40 %), respectively; odds ratio (OR) 0.25 (0.11 – 0.56); P < 0.001, as were the rates for the combined endpoint (HGD/EAC): 0.24 % (0.09 % – 0.32 %) vs. 0.76 % (0.43 % – 0.89 %), respectively; OR 0.35 (0.21 – 0.58); P < 0.001. There was no significant heterogeneity among studies. Conclusion The results demonstrate significantly lower rates of neoplastic progression in NDBE patients with SSBE compared with LSBE. BE length can easily be used for risk stratification purposes for NDBE patients undergoing surveillance endoscopy and consideration should be given to tailoring surveillance intervals based on BE length in future US guidelines.

Neoplastic Progression in Patients with Short Segment Barrett's Esophagus: Long-Term Follow-up of Over a 1000 Patients in a Multi-Center Consortium

2017 ◽  
Vol 152 (5) ◽  
pp. S456
Author(s):  
Sreekar Vennelaganti ◽  
Sravanthi Parasa ◽  
Prashanth Vennalaganti ◽  
Srinivas Gaddam ◽  
Manon Spaander ◽  
...  
Keyword(s):  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Neoplastic Progression ◽  
Short Segment ◽  
Long Term Follow Up

817 The SURF-Trial Pre-Assessment Cohort: A Multivariable Model Accurately Predicts Neoplastic Progression in Barrett's Esophagus Patients With Low-Grade Dysplasia

2015 ◽  
Vol 148 (4) ◽  
pp. S-159 ◽  
Author(s):  
Lucas C. Duits ◽  
Cary C. Cotton ◽  
Kai Yi N. Phoa ◽  
Fiebo T. Ten Kate ◽  
Cees A. Seldenrijk ◽  
...  
Keyword(s):  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Low Grade ◽  
Neoplastic Progression ◽  
Multivariable Model ◽  
Low Grade Dysplasia
Sign in / Sign up

Export Citation Format

Share Document